Tissue Plasminogen Activator for preclinical stroke research: Neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model

Tissue plasminogen activator (tPA) is the only approved thrombolytic therapy for acute ischemic stroke, yet many patients do not recanalize. Enhancing thrombolytic efficacy of tPA is a major focus of stroke research. Traditionally, a “rat dose” of 10 mg/kg has been used in rodent models. Recent stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomkins, Amelia J., Hood, Rebecca J., Levi, Christopher R., Spratt, Neil J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629197/
https://www.ncbi.nlm.nih.gov/pubmed/26522691
http://dx.doi.org/10.1038/srep16026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629197/
https://www.ncbi.nlm.nih.gov/pubmed/26522691
http://dx.doi.org/10.1038/srep16026

Ejemplares similares